# Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

> **NCT04758650** · PHASE2 · UNKNOWN · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 140 (estimated)

## Conditions studied

- Solid Malignancy Located in the Head and Neck
- Cancer
- Carotid Stenosis
- Atherosclerosis of Artery
- Hodgkin Lymphoma, Adult
- Non Hodgkin Lymphoma
- HLH
- Cardiac Sarcoidosis
- Sarcoidosis

## Interventions

- **DRUG:** 68GaNOTA-Anti-MMR-VHH2

## Key facts

- **NCT ID:** NCT04758650
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-26
- **Primary completion:** 2025-01-26
- **Final completion:** 2025-01-26
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04758650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04758650, "Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04758650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*